Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBT Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBT Margin for 12 consecutive years, with 162.19% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 62143.0% to 162.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 310.37% through Dec 2025, up 249496.0% year-over-year, with the annual reading at 310.37% for FY2025, 249496.0% up from the prior year.
  • EBT Margin for Q4 2025 was 162.19% at ImmunityBio, up from 209.94% in the prior quarter.
  • The five-year high for EBT Margin was 162.19% in Q4 2025, with the low at 735700.0% in Q1 2022.
  • Average EBT Margin over 5 years is 124844.02%, with a median of 45139.93% recorded in 2023.
  • The sharpest move saw EBT Margin tumbled -67780432bps in 2022, then skyrocketed 70331583bps in 2023.
  • Over 5 years, EBT Margin stood at 23474.87% in 2021, then tumbled by -532bps to 148345.21% in 2022, then fell by -13bps to 167952.52% in 2023, then surged by 100bps to 783.62% in 2024, then surged by 79bps to 162.19% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 162.19%, 209.94%, and 349.31% for Q4 2025, Q3 2025, and Q2 2025 respectively.